Harbor Investment Advisory LLC Has $4.36 Million Position in AbbVie Inc. $ABBV

Harbor Investment Advisory LLC lessened its stake in AbbVie Inc. (NYSE:ABBV) by 9.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 20,050 shares of the company’s stock after selling 2,042 shares during the period. Harbor Investment Advisory LLC’s holdings in AbbVie were worth $4,361,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in ABBV. Brighton Jones LLC boosted its position in AbbVie by 17.4% during the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock valued at $4,072,000 after acquiring an additional 3,401 shares during the last quarter. Revolve Wealth Partners LLC grew its holdings in AbbVie by 72.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after acquiring an additional 3,064 shares during the period. Schnieders Capital Management LLC. raised its position in shares of AbbVie by 5.0% in the 2nd quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock worth $3,056,000 after acquiring an additional 789 shares in the last quarter. Ieq Capital LLC raised its position in shares of AbbVie by 4.6% in the 2nd quarter. Ieq Capital LLC now owns 120,035 shares of the company’s stock worth $22,281,000 after acquiring an additional 5,274 shares in the last quarter. Finally, Worldquant Millennium Advisors LLC raised its position in shares of AbbVie by 117.3% in the 2nd quarter. Worldquant Millennium Advisors LLC now owns 1,135,034 shares of the company’s stock worth $210,685,000 after acquiring an additional 612,702 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

Wall Street Analyst Weigh In

ABBV has been the topic of several research analyst reports. BMO Capital Markets restated an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Canaccord Genuity Group lifted their target price on AbbVie from $265.00 to $273.00 and gave the stock a “buy” rating in a report on Tuesday, June 23rd. Guggenheim reissued a “buy” rating and issued a $249.00 price target on shares of AbbVie in a research note on Friday, May 1st. DZ Bank upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a report on Thursday, April 30th. Finally, Evercore set a $235.00 price objective on shares of AbbVie in a research report on Friday, May 15th. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $253.81.

AbbVie Stock Down 1.1%

Shares of ABBV opened at $251.45 on Wednesday. The business’s fifty day moving average is $216.92 and its 200 day moving average is $219.56. AbbVie Inc. has a 12-month low of $184.38 and a 12-month high of $255.99. The stock has a market cap of $444.26 billion, a P/E ratio of 123.87, a P/E/G ratio of 0.78 and a beta of 0.32.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, beating analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The business had revenue of $15 billion during the quarter, compared to analyst estimates of $14.72 billion. During the same quarter in the previous year, the business posted $2.46 EPS. AbbVie’s quarterly revenue was up 12.4% on a year-over-year basis. On average, analysts expect that AbbVie Inc. will post 14.28 EPS for the current year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.8%. AbbVie’s payout ratio is presently 340.89%.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie and Genmab reported positive Phase 3 results for Epkinly/epcoritamab in relapsed or refractory diffuse large B-cell lymphoma, with the trial meeting its primary endpoint and suggesting a potential label expansion. Article Title
• Positive Sentiment: AbbVie received positive CHMP opinions in Europe for Rinvoq in severe alopecia areata and non-segmental vitiligo, which could broaden the drug’s addressable market and add future sales momentum if approved. Article Title
• Positive Sentiment: AbbVie’s newly announced $10.9 billion Apogee acquisition and other partnership milestones underscore management’s willingness to invest heavily in future growth and deepen its immunology and neurology pipeline. Article Title
• Neutral Sentiment: Analysts slightly trimmed FY2026 earnings estimates, but the revised forecast remains close to consensus, so this looks like a modest rather than a major headwind. Article Title
• Negative Sentiment: U.S. lawmakers opened an investigation into AbbVie’s clinical trials in China, citing possible national security, ethical, and data-protection concerns. Article Title

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.